Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis

Suzuki,Koichi; Muto,Yuta; Ichida,Kosuke; Fukui,Taro; Takayama,Yuji; Kakizawa,Nao; Kato,Takaharu; Hasegawa,Fumi; Watanabe,Fumiaki; Kaneda,Yuji; Kikukawa,Rina; Saito,Masaaki; Tsujinaka,Shingo; Futsuhara,Kazushige; Takata,Osamu; Noda,Hiroshi; Miyakura,Yasuyuki; Kiyozaki,Hirokazu; Konishi,Fumio; Rikiyama,Toshiki

doi:10.3892/ol.2017.6338

Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis

Authors:
- Koichi Suzuki
- Yuta Muto
- Kosuke Ichida
- Taro Fukui
- Yuji Takayama
- Nao Kakizawa
- Takaharu Kato
- Fumi Hasegawa
- Fumiaki Watanabe
- Yuji Kaneda
- Rina Kikukawa
- Masaaki Saito
- Shingo Tsujinaka
- Kazushige Futsuhara
- Osamu Takata
- Hiroshi Noda
- Yasuyuki Miyakura
- Hirokazu Kiyozaki
- Fumio Konishi
- Toshiki Rikiyama
View Affiliations

Affiliations: Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330‑8503, Japan, Department of Surgery, Nerima‑Hikarigaoka Hospital, Tokyo 179‑0072, Japan
Published online on: June 7, 2017 https://doi.org/10.3892/ol.2017.6338
Pages: 1491-1499
Copyright: © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Morphological response is considered an improved surrogate to the Response Evaluation Criteria in Solid Tumors (RECIST) model with regard to predicting the prognosis for patients with colorectal liver metastases. However, its use as a decision-making tool for surgical intervention has not been examined. The present study assessed the morphological response in 50 patients who underwent chemotherapy with or without bevacizumab for initially un‑resectable colorectal liver metastases. Changes in tumor morphology between heterogeneous with uncertain borders and homogeneous with clear borders were defined as an optimal response (OR). Patients were also assessed as having an incomplete response (IR), and an absence of marked changes was assessed as no response (NR). No significant difference was observed in progression‑free survival (PFS) between complete response/partial response (CR/PR) and stable disease/progressive disease (SD/PD), according to RECIST. By contrast, PFS for OR/IR patients was significantly improved compared with that for NR patients (13.2 vs. 8.7 months; P=0.0426). Exclusion of PD enhanced the difference in PFS between OR/IR and NR patients (15.1 vs. 9.3 months; P<0.0001), whereas no difference was observed between CR/PR and SD. The rate of OR and IR in patients treated with bevacizumab was 47.4% (9/19), but only 19.4% (6/31) for patients that were not administered bevacizumab. Comparison of the survival curves between OR/IR and NR patients revealed similar survival rates at 6 months after chemotherapy, but the groups exhibited different survival rates subsequent to this period of time. Patients showing OR/IR within 6 months appeared to be oncologically stable and could be considered as candidates for surgical intervention, including rescue liver resection. Comparing the pathological and morphological features of the tumor with representative optimal response, living tumor cells were revealed to be distributed within the area of vascular reconstruction induced by bevacizumab, resulting in a predictive value for prognosis in the patients treated with bevacizumab. The present findings provided the evidence for physicians to consider patients with previously un-resectable metastatic colorectal cancer as candidates for surgical treatment. Morphological response is a useful decision‑making tool for evaluating these patients for rescue liver resection following chemotherapy.

View Figures

View References

1	Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, et al: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 32 Suppl:52014. View Article : Google Scholar : PubMed/NCBI
2	Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siriwardena AK, Mason JM, Mullamitha S, Hancock HC and Jegatheeswaran S: Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol. 11:446–459. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 27:3677–3683. 2009. View Article : Google Scholar : PubMed/NCBI
5	Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 230:3093211999. View Article : Google Scholar
6	Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W and Starzl TE: Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery. 116:703–711. 1994.PubMed/NCBI
7	Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: Analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46 (10 Suppl). 1–31. 2003.
8	Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 77:1254–1262. 1996. View Article : Google Scholar : PubMed/NCBI
9	Viganò L, Capussotti L, Majno P, Toso C, Ferrero A, De Rosa G, Rubbia-Brandt L and Mentha G: Liver resection in patients with eight or more colorectal liver metastases. Br J Surg. 102:92–101. 2015. View Article : Google Scholar : PubMed/NCBI
10	Wei AC, Greig PD, Grant D, Taylor B, Langer B and Gallinger S: Survival after hepatic resection for colorectal metastases: A 10-year experience. Ann Surg Oncol. 13:668–676. 2006. View Article : Google Scholar : PubMed/NCBI
11	Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK and Ahn JB: Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: A single-institute, retrospective analysis in Asia. Oncology. 85:283–289. 2013. View Article : Google Scholar : PubMed/NCBI
12	Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF and Freudenberg LS: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 45:357–365. 2004.PubMed/NCBI
13	Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, Van den Borne B, Cole P, Sciot R, et al: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 39:2012–2020. 2003. View Article : Google Scholar : PubMed/NCBI
14	Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
15	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
16	Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C and Loyer EM: Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. Jama. 302:2338–2344. 2009. View Article : Google Scholar : PubMed/NCBI
17	Nishioka Y, Shindoh J, Yoshioka R, Gonoi W, Abe H, Okura N, Yoshida S, Oba M, Hashimoto M, Watanabe G, et al: Radiological morphology of colorectal liver metastases after preoperative chemotherapy predicts tumor viability and postoperative outcomes. J Gastrointest Surg. 19:1653–1661. 2015. View Article : Google Scholar : PubMed/NCBI
18	Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA and Vauthey JN: Optimal morphologic response to preoperative chemotherapy: An alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 30:4566–4572. 2012. View Article : Google Scholar : PubMed/NCBI
19	Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B and Gruenberger T: Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 17:2059–2065. 2010. View Article : Google Scholar : PubMed/NCBI
20	O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, et al: Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: Insights from imaging. Clin Cancer Res. 15:6674–6682. 2009. View Article : Google Scholar : PubMed/NCBI
21	Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
22	Shindoh J, Chun YS, Loyer EM and Vauthey JN: Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: The morphologic response criteria. Curr Colorectal Cancer Rep. 9:198–202. 2013. View Article : Google Scholar : PubMed/NCBI
23	Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar : PubMed/NCBI
24	NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspJanuary 1–2016
25	Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol. 24:3939–3945. 2006. View Article : Google Scholar : PubMed/NCBI
26	Yoshita H, Hosokawa A, Ueda A, Ando T, Kajiura S, Kato H, Kawabe H, Tomizawa G, Horikawa N, Yabuhita K, et al: Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. Digestion. 89:pp. 43–48. 2014; View Article : Google Scholar : PubMed/NCBI
27	Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN and Parks RW: Guidelines for resection of colorectal cancer liver metastases. Gut. 55 Suppl 3:iii1–8. 2006. View Article : Google Scholar : PubMed/NCBI
28	Stangl R, Altendorf-Hofmann A, Charnley RM and Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet. 343:1405–1410. 1994. View Article : Google Scholar : PubMed/NCBI
29	Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI